Validating Indonesian Prostate Cancer Risk Calculator (IPCRC) for predicting prostate cancer risk in Cipto Mangunkusumo Hospital Jakarta

F. Abshari, P. Yuri, M. I. Akbar, G. Wangge, C. A. Mochtar, R. Umbas, A. R.A.H. Hamid

Research output: Contribution to journalConference articleResearchpeer-review


Introduction: Prostate cancer is a progressive disease resulting in morbidity and mortality. The aim of this study is to assess the accuracy of Indonesian Prostate Cancer Risk Calculator (IPCRC) in predicting prostate cancer risk. Methods: Data were obtained retrospectively from medical records of suspected prostate cancer patients. Digital rectal examination, Prostate Spesific Antigen (PSA), and prostate volume were used as predictive parameters in IPCRC. Prostate biopsy was used as the diagnostic gold standard. The accuracy of IPCRC was validated using the ROC analysis. Results: Our study included 127 subjects. Median age of BPH and prostate cancer patients were 66 (52–85) and 69.5 (50–100). Median of PSA of BPH and prostate cancer patients were 10.2 (1.6–203.1) and 74.06 (6.94–1412) respectively. The prostate volume of BPH patients 47.9 (13.74–108) compared to prostate cancer patients 50.25 (19.2–107). The largest AUC of IPCRC is 0.907 (95% CI 0.84–0.97). We determined three cutoff points (15%, 20%, and 25%) with the sensitivity (65,4% to 88,5%) and specificity (81,8% to 89,9%). Conclusion: IPCRC is accurate for predicting prostate cancer in our population. Further validation is needed in other population.

Original languageEnglish
Pages (from-to)6981-6983
Number of pages3
JournalAdvanced Science Letters
Issue number7
Publication statusPublished - Jul 2017
Externally publishedYes


  • BPH
  • Prostate Biopsy
  • Prostate Cancer

Cite this